Health
Candidate monoclonal antibody shows hope as COVID-19 treatment – News-Medical.Net
Researchers in the United States have described the effectiveness of a candidate monoclonal antibody currently being evaluated in a Phase 1 trial as a therapy for coronavirus disease 2019 (COVID-19) and its causative agent, severe acute respiratory syndrome c…
Researchers in the United States have described the effectiveness of a candidate monoclonal antibody currently being evaluated in a Phase 1 trial as a therapy for coronavirus disease 2019 (COVID-19) and its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The drug, called CPI-006, targets an immune signaling molecule called CD73 and activates CD73POS B cells, which subsequently promotes antibody production and differentiation into B cells.
In vitro, CPI-006 induce…
-
Noosa News23 hours agoIan McLeod, 95, powering his farm ute and house on waste vegetable oil
-
Noosa News24 hours agoHonouring James Ackerman and his legacy, 10 years after a rugby league tragedy
-
Noosa News22 hours agoBus driver bashed in South Brisbane
-
Noosa News18 hours agoWas Sir Joh ‘God’, as David Littleproud says, or a template for Trump?